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When grown in the standard Dulbecco's medium the human liver derived Hep G2 hepatoma cell line shows only 10-20 % 
of the cytochrome P-450-dependent mixed function oxidase (MFO) activity of freshly isolated human adult hepatocytes. 
However, the MFO activities and, to a lesser extent, the activities of UDP-glucuronyltransferase and glutathione-S-trans- 
ferase can be increased by altering the composition of the growth medium. Modified Earle's medium was more effective 
in this respect han Williams' E medium and increased the O-dealkylations of ethoxyresorufin, benzyloxyresorufin a d 
pentoxyresorufin 50-, 30- and 10-fold, respectively. 
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1. INTRODUCTION 
There have been a number of reports recently 
suggesting that human hepatoma cell lines which 
retain differentiated parenchymal functions may 
provide an in vitro system for studying drug 
metabolism and cytotoxicity directly in man. Cer- 
tain cell lines, including Hep G2, Hep 3B and SK- 
Hep-l ,  can carry out cytochrome P-450-dependent 
mixed function oxidase (MFO) and conjugation 
reactions [1-4] and are capable of activating ben- 
zo(a)pyrene, aflatoxin B~ and cyclophosphamide 
to cytotoxic and mutagenic metabolites [2,5-7]. 
The drug metabolising enzyme activities of the 
human liver derived hepatoma cell line, I--Iep G2, 
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have recently been compared with those in freshly 
isolated human adult hepatocytes [8]. MFO ac- 
tivities towards three substrates were found to be 
5-10-fold lower in the Hep G2 cells grown in the 
standard Dulbecco's medium than in the 
hepatocytes, whereas the activities of the con- 
jugating enzymes, GT and GST were similar in the 
two cell types [9]. Hep G2 is a highly differentiated 
cell line which has retained many of the specialised 
functions normally lost by hepatocytes in culture 
[10]. The loss of MFO activities in Hep G2 ceils 
may have occurred either as a consequence of the 
original transformation of the hepatocytes to 
tumour cells or, alternatively, as a result of being 
grown in inappropriate culture conditions. 
MFO activities are known to be unstable during 
primary culture of hepatocytes from both animals 
and man [11-13], and are markedly influenced by 
the culture conditions, for example medium and 
substratum composition [12,14]. The addition of 
hormones, nicotinamide, metyrapone and the ex- 
clusion of L-cysteine and L-cystine from the 
culture medium have all been reported to improve 
the maintenance of MFO activities in cultured rat 
hepatocytes [11,15,16]. Albumin production in 
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Huh 6 human hepatoma cel ls  has  been  shown to  
respond to  cu l tu re  cond i t ions  and  was  increased  
when the  cel ls were  grown on  f ib ronect in  o r  
lamin in  subst ra ta  [17]. The  a im o f  th is  s tudy  was  
to  determine  whether  d rug  metabo l i s ing  enzyme 
act iv i t ies ,  par t i cu la r ly  those  o f  MFO,  in Hep  G2 
cel ls  cou ld  be  mod i f ied  by  a l te r ing  the  compos i t ion  
o f  the  growth  med ium.  The  enzyme act iv i t ies  o f  
cel ls  g rown in Du lbecco 's  med ium were  compared  
w i th  those  o f  cel ls  g rown in Wi l l i ams '  E o r  
mod i f ied  Ear le ' s ,  the  two  med ia  wh ich  were  the  
most  e f fec t ive  fo r  ma inta in ing  the  cytochrome 
P -450  content  o f  cu l tu red  ra t  hepatocytes  [12]. 
2. MATERIALS  AND METHODS 
2.1. Materials 
Flow Laboratories upplied the Dulbecco's and Williams' E 
media and fetal calf serum was purchased from Gibco. 
l-Naphthol, 1-naphthol glucuronide, bilirubin, UDP- 
glucuronic acid, NADPH and bromobenzene were obtained 
from Sigma. Resorufin, methoxyresorufin, ethoxyresorufin, 
pentoxyresorufin a d benzyloxyresorufin were synthesized as 
described by Burke and Mayer [18]. The Hep G2 cell line was 
obtained from Professor C.N. Hales, Department of Clinical 
Biochemistry, Addenbrooke's Hospital, Cambridge. 
2.2. Culture of  Hep G2 cells 
Hep G2 cells were routinely grown in Dulbecco's modifica- 
tion of Eagle's medium containing 10070 (v/v) fetal calf serum 
and split 1:3 every 7 days (seeding density 3.5 × 106 cells in a 
75 cm 2 flask). When the growth medium was altered, the cells 
were allowed to grow for at least 7 days in the new medium 
before enzyme activities were measured. The medium was 
renewed routinely 3 and 6 days after passage and all enzyme ac- 
tivity measurements were carried out on confluent cells 7 days 
after subculture. The composition of modified Eagle's medium 
was as described previously [19] except hat 0.25 mM L-cysteine 
was added. 
2.3. Incubation of  Hep G2 cells for  toxicity experiments 
Suspensions of Hep G2 cells were prepared as described 
Table 1 
Drug metabolising enzyme activities and glutathione content of Hep G2 cells cultured in 
different media 
Reaction rate 
Dulbecco's Williams' E Earle's 
medium medium medium 
MROD a 1.0 ___ 0.1 (3) 2.7 5: 0.3* (5) 49.8 _+ 5.9* (3) 
(100070) (27007o) (498%) 
EROD a 2.7 5:0.2 (3) 6.1 5: 0.5* (5) 127.1 _+ 12.4" (3) 
(100°70) (22607o) (4700070) 
BROD a 0.7 5:0.1 (3) 1.7 _+ 0.4* (5) 20.7 _+ 3.0* (3) 
(100070) (243 07o) (2957 070) 
PROD a 0.4 ___ 0.05 (3) 0.8 ___ 0.2 (5) 3.0 5: 0.I* (3) 
(100070) (200°70) (750%) 
1-Naphthol GT b 0.57 _+ 0.05 (5) 0.68 _+ 0.15 (3) 1.03 + 0.05* (6) 
(100070) (119%) (181070) 
Bilirubin GT b 1.10 _+ 0.24 (6) 1.67 _-2- 0.15 (6) 4.51 _+ 0.38* (3) 
(100070) (152%) (410070) 
CDNB GST b 7.20_+ 0.20 (3) 6.72 + 0.28 (3) 16.13 + 1.11" (3) 
(100070) (93°7o) (22407o) 
GSH content ~ 18.02 + 1.08 (3) 15.85 + 0.39 (3) 29.70 _+ 2.98* (3) 
(100°7o) (88°70) (165070) 
a Reaction rate results are expressed in pmol/min per mg protein 
b Reaction rate results are expressed in nmol/min per mg protein 
c Reaction rate results are expressed in nmol/mg protein 
The values are means _+ SE, with the numbers of experiments in parentheses. The values 
obtained in cells cultured in Williams' E and modified Earle's media were expressed as 
a percentage of those obtained in cells cultured in Dulbecco's medium and the percentages 
are shown in brackets. * P < 0.05, by one way analysis of variance followed by Dunnett's 
test. Significance values refer to differences in enzyme activities and GSH content between 
cells grown in Dulbecco's medium and those grown in the other two media 
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previously [9] and incubated in 50 ml round bottomed flasks in 
Krebs-Henseleit buffer, pH 7.4, containing 10 mM Hepes at 
37°C under an atmosphere of 95% 02:5°70 COz. The effect of 
10 mM bromobenzene on cell viability was assessed using 
Trypan blue exclusion. In some experiments 0.5 mM 
metyrapone was included in the incubations as an inhibitor of 
the MFO system. 
2.4. Analytical methods 
Enzyme activities were measured on cell homogenates 
prepared in 0.1 M sodium phosphate buffer, pH 7.6, as de- 
scribed previously [9]. MFO activities were measured by the O- 
dealkylation of MROD, EROD, PROD and BROD, which are 
metabolised by different isoenzymes of cytochrome P-450 in the 
rat [20], as described previously [9]. GST activity was measured 
using 50gM CDNB in the presence of excess reduced 
glutathione (1 raM) by direct spectrophotometry as described 
by Habig and Jakoby [21]. Intracellular GSH was determined 
fluorimetrically [22] after scraping the cultured cells into 6.5% 
(w/v) trichloroacetic acid. GT activity was measured either us- 
ing l-naphthol (50/~M) in the presence of 0.5 mM UDP- 
glucuronic acid and 5 mM MgCIz by continuous fluorescence 
detection of the glucuronide formed [23] or using 0.4 mM 
bilirubin in the presence of 4 mM UDP-glucuronic acid and 
10 mM MgCI2 by the diazotization procedure as described in 
[24]. 
3. RESULTS 
The activities of MFO, GT and GST and the 
GSH content of Hep G2 cells grown in Dulbecco's, 
Williams' E and modified Earle's media are shown 
in table 1. The lowest MFO activities were in the 
cells grown in Dulbecco's medium, while the 
culture in Williams' E medium resulted in an ap- 
prox. 2-fold increase in all the activities. Com- 
pared with Dulbecco's medium, cultures in the 
modified Earle's medium increased MROD activi- 
ty 50-fold, EROD 47-fold, BROD 30-fold and 
PROD 10-fold. The activities of GT and GST were 
also increased by culture in the modified Earle's 
medium, although the effect of medium composi- 
tion on the activities of these two enzymes was not 
as marked as the effect on MFO. GSH content was 
2-fold higher in cells grown in modified Earle's 
medium. 
Fig. 1 shows that, compared with the response of 
cells grown in Dulbecco's medium, the toxicity of 
bromobenzene was markedly increased in cells 
grown in Williams' E medium and was greatest in 
those grown in modified Earle's medium. The tox- 
icity of bromobenzene to Hep G2 cells grown in 
Williams' E medium was almost completely 
prevented by the presence of 0.5 mM metyrapone. 
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Fig.1. The effect of 10 mM bromobenzene on the viability of 
Hep G2 cells grown in Dulbecco's (©, N = 2), Williams' E (e, 
N = 3) and modified Earle's (Lx, N = 3) media. (A) The effect 
of 0.5 mM metyrapone on the toxicity of bromobenzene in cells 
grown in Williams' E medium (N = 3). Error bars represent 
either the SE, where N > 2, or the range, where N = 2. 
4. DISCUSSION 
The results shown here suggest hat the absence 
of MFO activities in the Hep G2 cell line is due to 
a large extent to the use of inappropriate culture 
conditions for growing the cells. 
The modified Earle's medium increased the 
MFO activities expressed by Hep G2 cells in a 
substrate specific manner, exerting the greatest ef- 
fect on EROD and MROD, which are probes for 
a 3-methylcholanthrene induced form of 
cytochrome P-450 in the rat [20]. There was least 
effect on PROD activity, which is a probe for a 
phenobarbitone induced cytochrome P-450 in rat 
liver. This medium is supplemented with hydrocor- 
tisone (10 -4 M) and 5-aminolaevulinic acid 
(10 -4 M), and these supplements were thought to 
be responsible for its efficiency in maintaining the 
level and function of cytochrome P-450 in cultured 
hepatocytes [12,13] and Hep G2 cells. However, 
the addition of hydrocortisone and 5-amino- 
laevulinic acid to either Dulbecco's or Williams' E 
medium did not significantly increase MFO ac- 
tivities (not shown). 
The presence of L-cysteine or L-cystine in 
modified Earle's medium had previously been 
found to be detrimental to the maintenance of 
cytochrome P-450 content and MFO activities in 
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cultured rat hepatocytes [15], and these amino 
acids were replaced by L-methionine. However, 
Hep G2 cells cannot use L-methionine for GSH 
synthesis [9] and do not survive in modified Earle's 
medium without L-cysteine. We have found that, 
in contrast to hepatocytes, the presence of L- 
cysteine in modified Earle's medium improved the 
expression of MFO, GT and GST activities in the 
Hep G2 cells approx. 2-fold (not shown). 
Bromobenzene is metabolised to a cytotoxic 
epoxide metabolite by the MFO system [25] and 
the increase in bromobenzene-induced toxicity to 
Hep G2 cells observed in Williams' E and Earle's 
medium reflects the increased levels of MFO activi- 
ty in these media. The toxicity of bromobenzene to 
the Hep G2 cells was prevented by including 
0.5 mM metyrapone, an inhibitor of the MFO 
system, in the incubations. 
The effects of medium composition on the ac- 
tivities of GT and GST were less dramatic than on 
the MFO system. The conjugation enzyme ac- 
tivities were also more stable than the MFO ac- 
tivities in cultured rat and human hepatocytes and 
in these cultures also they are relatively unaffected 
by changes in medium composition [13,26]. The 
increase in GST activity observed in Hep G2 cells 
grown in modified Earle's medium was not simply 
due to the increase in the intracellular GSH, since 
the GST activities were measured in cell 
homogenates in the presence of added excess GSH. 
Human hepatoma cell lines, such as Hep G2, 
have previously been thought to contain only low 
activities of the major drug metabolising enzymes. 
However, with the demonstration, in this paper, 
that the MFO activities, and to a lesser extent the 
GST and GT activities, of Hep G2 cells can be 
manipulated by medium composition, these cells 
become a powerful tool for investigating the 
potential hepatic metabolism and cytotoxicity of 
xenobiotics in man in vitro. 
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